PXN and lung cancer: A newly developed novel ST inhibitor, Lith-O-Asp, can inhibit lung cancer cell metastasis by inhibiting FAK/paxillin signaling and expressing antiangiogenic factors and is considered a potential antimetastatic therapy [171].